NCTId,BriefTitle,OverallStatus,StudyType,Phases,Conditions,LeadSponsorName,StartDate,StudyFirstPostDate,LastUpdatePostDate,Timestamp
NCT01847573,"Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy",TERMINATED,INTERVENTIONAL,"PHASE1, PHASE2",Duchenne Muscular Dystrophy,Processa Pharmaceuticals,2013-05,2013-05-07,2020-09-03,2024-11-08T07:17:24.799256
NCT03067831,Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy,UNKNOWN,INTERVENTIONAL,"PHASE1, PHASE2",Duchenne Muscular Dystrophy,Stem Cells Arabia,2015-09,2017-03-01,2020-03-17,2024-11-08T07:17:24.799256
NCT02369731,Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD),ACTIVE_NOT_RECRUITING,OBSERVATIONAL,,"Muscular Dystrophy, Duchenne",PTC Therapeutics,2015-04-30,2015-02-24,2024-10-09,2024-11-08T07:17:24.799256
